[Clinical study of the month. The LIPID study: "long-term intervention with pravastatin in ischaemic disease"]

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Coronary heart disease (CHD) remains a leading cause of mortality worldwide.
• Effective secondary prevention strategies are crucial for managing patients with existing CHD.
• The role of statins in patients with varying cholesterol levels requires further elucidation.

Purpose of the Study:

• To evaluate the efficacy of pravastatin in reducing cardiovascular events and mortality in patients with CHD.
• To determine if the benefits of pravastatin extend to patients with baseline cholesterol levels considered normal.

Main Methods:

• The LIPID study was a randomized, double-blind, placebo-controlled trial involving 9014 patients with CHD.
• Participants had total cholesterol levels ranging from 155 to 271 mg/dl.
• Patients were followed for a mean of 6.1 years, receiving either pravastatin (40 mg/day) or a placebo.

Main Results:

• Pravastatin significantly reduced CHD death rate by 24% (p < 0.001), overall mortality by 22%, and cardiovascular outcomes by 20-29%.
• These benefits were observed across all initial cholesterol concentrations.
• Significant reductions in CHD death or nonfatal myocardial infarction were noted even with total cholesterol < 213 mg/dl and LDL cholesterol < 135 mg/dl.

Conclusions:

• Pravastatin is effective in secondary prevention for patients with CHD, lowering mortality and cardiovascular event rates.
• The cardioprotective effects of pravastatin are evident even in patients with baseline cholesterol levels within the 'normal' range.
• These findings support the use of statin therapy for secondary prevention in a broad spectrum of CHD patients.